Literature DB >> 21039424

Intercellular adhesion molecule-1 on synovial cells attenuated interleukin-6-induced inhibition of osteoclastogenesis induced by receptor activator for nuclear factor κB ligand.

M Suzuki1, M Hashizume, H Yoshida, M Shiina, M Mihara.   

Abstract

In a co-culture of osteoclast precursor cells and synovial cells, interleukin-6 (IL-6) induces osteoclast formation. In contrast, in a monoculture of osteoclast precursor cells, IL-6 directly suppresses receptor activator for nuclear factor κB ligand (RANKL)-induced differentiation of osteoclast precursor cells into osteoclasts. In the present study, we explored why the effect of IL-6 differed between the monoculture and the co-culture systems. In the monoculture, mouse osteoclast precursor cell line, RAW 264·7 (RAW) cells were cultured with soluble RANKL (sRANKL) for 24 h or 3 days. sRANKL increased both expression of osteoclastogenesis marker, tartrate-resistant acid phosphatase isoform 5b (TRAP5b) and nuclear factor of activated T cells cytoplasmic 1 (NFATc1), whereas the co-addition of IL-6 decreased them both in a dose-dependent manner. In the co-culture, RAW cells and human synovial cell line, SW982 cells were cultured with IL-6+soluble IL-6 receptor (sIL-6R) for 3 days. TRAP5b and NFATc1 expression reduced by IL-6 was increased by the addition of SW982 cells in a manner dependent upon the number of added cells. IL-6+sIL-6R treatment significantly induced RANKL production in SW982 cells, and anti-RANKL antibody inhibited IL-6+sIL-6R-induced osteoclastogenesis. SW982 cells expressed high levels of ICAM-1 originally, and ICAM-1 expression was increased significantly by IL-6+sIL-6R. Anti-ICAM-1 antibody suppressed IL-6-induced osteoclastogenesis. Finally, in the monoculture system, addition of sICAM-1 dose-dependently restored the expression of TRAP5b reduced by IL-6. Similar results were obtained when the formation of TRAP-positive multi-nuclear cells were examined using mouse bone marrow cells. In conclusion, IL-6 gave different results in the co-culture and monoculture systems because in the co-culture, ICAM-1 from the synovial cells restored osteoclastogenesis suppressed by IL-6.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039424      PMCID: PMC3010915          DOI: 10.1111/j.1365-2249.2010.04276.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

Review 1.  Avidity regulation of integrins: the driving force in leukocyte adhesion.

Authors:  Y van Kooyk; C G Figdor
Journal:  Curr Opin Cell Biol       Date:  2000-10       Impact factor: 8.382

2.  Purification and characterization of soluble human IL-6 receptor expressed in CHO cells.

Authors:  K Yasukawa; T Saito; T Fukunaga; Y Sekimori; Y Koishihara; H Fukui; Y Ohsugi; T Matsuda; H Yawata; T Hirano
Journal:  J Biochem       Date:  1990-10       Impact factor: 3.387

3.  Beta 2-integrin LFA-1 signaling through phospholipase C-gamma 1 activation.

Authors:  S B Kanner; L S Grosmaire; J A Ledbetter; N K Damle
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

4.  Characterization of anti-mouse interleukin-6 receptor antibody.

Authors:  Makoto Okazaki; Yoshiki Yamada; Norihiro Nishimoto; Kazuyuki Yoshizaki; Masahiko Mihara
Journal:  Immunol Lett       Date:  2002-12-03       Impact factor: 3.685

5.  Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis.

Authors:  T Hirano; T Matsuda; M Turner; N Miyasaka; G Buchan; B Tang; K Sato; M Shimizu; R Maini; M Feldmann
Journal:  Eur J Immunol       Date:  1988-11       Impact factor: 5.532

6.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

Authors:  J Li; I Sarosi; X Q Yan; S Morony; C Capparelli; H L Tan; S McCabe; R Elliott; S Scully; G Van; S Kaufman; S C Juan; Y Sun; J Tarpley; L Martin; K Christensen; J McCabe; P Kostenuik; H Hsu; F Fletcher; C R Dunstan; D L Lacey; W J Boyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.

Authors:  H Takayanagi; H Iizuka; T Juji; T Nakagawa; A Yamamoto; T Miyazaki; Y Koshihara; H Oda; K Nakamura; S Tanaka
Journal:  Arthritis Rheum       Date:  2000-02

8.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.

Authors:  E M Gravallese; C Manning; A Tsay; A Naito; C Pan; E Amento; S R Goldring
Journal:  Arthritis Rheum       Date:  2000-02

9.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.

Authors:  F A Houssiau; J P Devogelaer; J Van Damme; C N de Deuxchaisnes; J Van Snick
Journal:  Arthritis Rheum       Date:  1988-06

10.  Phenotypic characterization of a human synovial sarcoma cell line, SW982, and its response to dexamethasone.

Authors:  Taisuke Yamazaki; Takashi Yokoyama; Hiromi Akatsu; Takashi Tukiyama; Takayoshi Tokiwa
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Sep-Oct       Impact factor: 2.416

View more
  9 in total

Review 1.  Pathways for bone loss in inflammatory disease.

Authors:  Tobias Braun; Georg Schett
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

2.  Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β.

Authors:  Anita Ignatius; Philipp Schoengraf; Ludwika Kreja; Astrid Liedert; Stefan Recknagel; Sebastian Kandert; Rolf E Brenner; Marion Schneider; John D Lambris; Markus Huber-Lang
Journal:  J Cell Biochem       Date:  2011-09       Impact factor: 4.429

Review 3.  Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts.

Authors:  Rebecca Baum; Ellen M Gravallese
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

4.  Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats.

Authors:  Hoi-Kei Lon; Debra C DuBois; Justin C Earp; Richard R Almon; William J Jusko
Journal:  Pharmacol Res Perspect       Date:  2015-08-03

5.  New insight into fat, muscle and bone relationship in women: determining the threshold at which body fat assumes negative relationship with bone mineral density.

Authors:  Pei-Yang Liu; Jasminka Z Ilich; Ken Brummel-Smith; Sunita Ghosh
Journal:  Int J Prev Med       Date:  2014-11

6.  NDRG2 Expression Decreases Tumor-Induced Osteoclast Differentiation by Down-regulating ICAM1 in Breast Cancer Cells.

Authors:  Bomi Kim; Sorim Nam; Ji Hyun Lim; Jong-Seok Lim
Journal:  Biomol Ther (Seoul)       Date:  2016-01-01       Impact factor: 4.634

7.  Complement receptor C5aR1 on osteoblasts regulates osteoclastogenesis in experimental postmenopausal osteoporosis.

Authors:  Jasmin Maria Bülow; Nikolai Renz; Melanie Haffner-Luntzer; Verena Fischer; Astrid Schoppa; Jan Tuckermann; Jörg Köhl; Markus Huber-Lang; Anita Ignatius
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

8.  Etidronate prevents dystrophic cardiac calcification by inhibiting macrophage aggregation.

Authors:  Carolin Bauer; Olivier le Saux; Viola Pomozi; Redouane Aherrahrou; Rene Kriesen; Stephanie Stölting; Annett Liebers; Thorsten Kessler; Heribert Schunkert; Jeanette Erdmann; Zouhair Aherrahrou
Journal:  Sci Rep       Date:  2018-04-11       Impact factor: 4.379

9.  A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy.

Authors:  Mingxiang Cai; Li Yang; Shufan Zhang; Jiafan Liu; Yao Sun; Xiaogang Wang
Journal:  Int J Nanomedicine       Date:  2017-10-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.